Advanced Breast Cancer Outcome Improved with Femara, Ribociclib Combination
News
Combining Norvartis‘ CDK4/6 inhibitor ribociclib with Femara (letrozole) may be a promising first-line therapy for hormone receptor (HR)-positive breast cancer patients, according to recent data from a Phase 3 clinical ... Read more